{"title":"Protocolo de evaluación de los biomarcadores moleculares y celulares en el cáncer de mama","authors":"A. Escudero García, P. Pérez Segura","doi":"10.1016/j.med.2025.01.005","DOIUrl":null,"url":null,"abstract":"<div><div>Breast cancer is a heterogeneous disease with a highly variable clinical behavior. It is important to know the prognostic and predictive factors in order to define patients’ risk after diagnosis and to be able to select the best treatment in each case. Prognostic markers include clinical (age, disease stage), pathological (tumor grade, Ki67, estrogen receptor, human epidermal growth factor receptor 2 (HER2), histology), and molecular (Oncotype Dx®, Mammaprint®, Endopredict®, or Prosigma® provide prognostic information in luminal disease) factors. This protocol reviews the immunohistochemical and molecular classification of breast cancer as well as its main prognostic and/or predictive factors.</div></div>","PeriodicalId":100912,"journal":{"name":"Medicine - Programa de Formación Médica Continuada Acreditado","volume":"14 24","pages":"Pages 1439-1442"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicine - Programa de Formación Médica Continuada Acreditado","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0304541225000101","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Breast cancer is a heterogeneous disease with a highly variable clinical behavior. It is important to know the prognostic and predictive factors in order to define patients’ risk after diagnosis and to be able to select the best treatment in each case. Prognostic markers include clinical (age, disease stage), pathological (tumor grade, Ki67, estrogen receptor, human epidermal growth factor receptor 2 (HER2), histology), and molecular (Oncotype Dx®, Mammaprint®, Endopredict®, or Prosigma® provide prognostic information in luminal disease) factors. This protocol reviews the immunohistochemical and molecular classification of breast cancer as well as its main prognostic and/or predictive factors.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
